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08 Did You Know?
CENTER  FOR  CLINICAL  &
TRANSLATIONAL  SCIENCE
UMASS  MEDICAL  SCHOOL  CCTS  NEWS  LETTER
N3C is an NIH NCATS-sponsored analytics
platform that contains clinical data from the
electronic health records of people who were
tested for the novel coronavirus or who have
had related symptoms .  UMass Medical School
was one of the first 12 vanguard sites to deposit
COVID data to N3C . We are happy to announce
that we have executed all the regulatory work
required to facilitate access to N3C Data
Enclave for our UMMS and Memorial
investigators .
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CTSA sites across the country are continuing to contribute data to N3C
with the goal of creating a harmonized data set from all 60+ CTSA’s. Currently,
the N3C Data Enclave boasts upwards of 600K COVID related cohorts (>60K
COVID positive data) from 15 sites. Access to de-identified or identified data
sets is available: a) access to de-identified or safe harbor datasets does not
require institutional IRB approval; and b) access to datasets with PHI requires
institutional IRB approval. More information on the N3C Data Enclave is
available at https://ncats.nih.gov/n3c. For any questions or assistance in
gaining access to N3C Data Enclave, contact our UMCCTS - N3C admin, Mahesh
Vangala Mahesh at Vangala@umassmed.edu .
THE NATIONAL COVID COHORT
COLLABORATIVE (N3C)
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At the UMass Integrative Biomarker Center (InBioC),
we look forward to working with investigators to
provide relevant and timely proteomics or RNA
measurements (i.e. microRNA, mRNA, etc) to support
clinical projects for validation, preliminary data, grant
submissions, etc.  We do require that data generated
as part of this initiative be made available to other
investigators as part of a virtual data repository that
will allow data sharing and/or reanalysis.  We will
provide “Seed Money” along with support for
investigators to generate data needed for programs,
grants, and projects. Initially, these will be awarded in
the range of 1-5K.  Please see our webpage
(https://www.umassmed.edu/InBioC/) to learn more.
UMASS INTEGRATIVE BIOMARKER CENTER
(INBIOC) IS OPEN FOR BUSINESS
U M M S  C C T S  N E W S L E T T E R
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The National COVID Cohort Collaborative (N3C) Data Enclave is now
open to scientists looking for evidence-based answers to COVID-19
research questions.  This centralized and secure national data analytics
platform is for COVID-19 research, including studying potential risk 
THE NATIONAL COVID COHORT COLLABORATIVE (N3C)
The Center for Advancing Point of Care Therapeutics
(CAPCaT) has been designated as a national test center for
the NIH Rapid Acceleration of Diagnostics (RADx) program.
Our Center is looking for experienced clinical research
nurses with an interest in working with people undergoing 
COVID-19
CLINICAL RESEARCH NURSES NEEDED 
FOR RADX STUDIES
COVID-19 testing to collect information and specimens in order to validate new
and innovative test devices coming to UMass from around the world. The positions
are available immediately. If you are interested or if you have any questions,
please contact Danielle Howard at
(Danielle.howard@umassmed.edu) or apply at
https://www.ummsjobs.com/job/5416/  or https://www.ummsjobs.com/job/5000/
To search for active Covid-19 clinical trials at
UMMS, please visit
https://www.conqueringdiseases.org/ .
Conquering Diseases is an easy to use web-based
search tool to find, share and save clinical studies
relevant to patients. It also provides educational
resources to help patients and families learn 
UCLINICAL TRIALS DATABASE
about and find clinical studies. It provides a patient-friendly and direct
way to learn about clinical studies and a secure environment to share
clinical study opportunities and communicate with study staff for
screening and enrollment into clinical studies.
UMMS update regarding human subjects research during the COVID-19
pandemic can be found here: https://umassmed.edu/ccts/covid-19/. This
website is updated frequently;  Last update Nov 25, 2020.
UMMS UPDATE
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factors, protective factors and long-term health consequences, as the pandemic
continues to evolve. Its data and analytics capabilities will grow over time. Learn
more about the N3C data and applying for access.
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EVENTS
Real-world data are routinely collected about the patient health
status or health care from a variety of sources (e.g., electronic health records
(EHRs); claims and billing; disease registries; patient-generated input; mobile
devices). Such data are increasingly used in research and development, especially
during the current pandemic. This Virtual Workshop will provide a forum for
presentations and discussions around the latest trends, and most up-to-date
methods of using real world data. The constructive and practical messages should
benefit principal investigators, research laboratory leaders, as well as users of
clinical research discoveries.  For more information visit:  
https://www.fnlm.org/product/real-world-data-and-electronic-health-records-in-clinical-research/
REAL WORLD DATA & ELECTRONIC HEALTH RECORDS IN CLINICAL
RESEARCH:  JANUARY 27, 2021 11:00 AM TO 1:00 PM
You are invited to attend two upcoming training webinars to learn how to utilize
the TriNetX platform to conduct research and support clinical trials utilizing
real-world data.  Basic Functionality Training is at 10:00 AM and Advanced Analytics
Training is at 8:00 AM on January 14th.  For more information visit:
https://mailchi.mp/trinetx/training-jan21-1467406?e=7790c5a783
 HOW TO USE REAL WORLD DATA TO SUPPORT YOUR         
 RESEARCH & CLINICAL TRIALS:  JANUARY 14, 2021
The Community Engagement and Collaboration Core of the UMass
Center for Clinical and Translation Science is offering the workshop “Developing
Messages that Move Non-Academic Audiences” on January 29, 2021 from 10:00 am –
12:00 pm.  Please register by January 27, 2021 to reserve your spot!  This workshop
will provide practical advice and hands-on exercises to turn your idea into a
powerful message.  Getting rid of jargon is only the first step. We’ll
help you frame your message, tailor it to your audience, and choose the right
way to communicate it. You’ll walk out the door with a plan! Bring something you
want to say to a non-academic audience.  Please register at
https://www.umassmed.edu/ccts/community/programs-and-resources/public-
engagement-project/
DEVELOPING MESSAGES THAT MOVE NON-ACADEMIC AUDIENCES
JANUARY 29, 2021 10:00 AM TO 12:00 PM
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U M M S  C C T S  N E W S L E T T E R
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NCATS invites innovators and multi-expert teams to participate in the NCATS
ASPIRE Reduction-to-Practice Challenge. The goal is the development of a platform
that scientists can use to advance their translational science relevant to
development and testing of new and safer treatments of pain, opioid use disorder
and overdose. NCATS anticipates that this integrated platform ultimately can be
generalized to address many of the roadblocks in automated chemistry. Stage 1 of
the Reduction-to-Practice Challenge opens Nov. 30, 2020, and submissions are due
by Feb. 28, 2021, at 5p.m. EST. For more information visit:
https://ncats.nih.gov/aspire/2020Challenge
NCATS ASPIRE:  REDUCTION-TO-PRACTICE CHALLENGE  
OPENS  11/30  & DUE  FEB .  28 ,  2021  AT  5  PM
This funding facilitates the development of faculty-to-faculty networks within the
University system.  Click on this link for more information:
https://umassmed.edu/ccts/funding/small-conference-grants/
CCTS SMALL CONFERENCE GRANTS:  
ROLLING  APPLICATION  DEADLINE
FUNDING
This program’s priorities are to support studies that impact clinical care and
research methodologies, support students/trainees, and provide access to funds to
generate pilot and preliminary data for external grant submissions. For more
information, visit: https://www.umassmed.edu/ccts/funding/spark-program/
CCTS SPARK PROGRAM: 
ROLLING  APPLICATION  DEADLINE
Drug Development Collaboratory: The purpose of this Funding Opportunity
Announcement (FOA) is to support intramural-extramural collaborations on
late-stage translational science projects between NCATS Therapeutic Development
Branch (TDB) and extramural researchers, for therapeutic development of small
molecules, biologics, or gene therapies. The UG3 phase will provide support for late
stage pre-clinical work and clinical trial planning that is conducted applicant
institutions. The goal of any collaboration with TDB is to enable an IND application
by the end of the UG3 phase. If UG3 milestones are met and an IND is cleared,
support may be provided for an early stage clinical trials in the UH3 phase that will
be conducted at the applicant institutions. Application due date:  February 9, 2021
For more information visit: https://grants.nih.gov/grants/guide/pa-files/PAR-20-301.html
DRUG DEVELOPMENT COLLABORATORY: 
DUE  FEBRUARY  9 ,  2021
U M M S  C C T S  N E W S L E T T E R
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FUNDING
The purpose of this interagency program solicitation is to support the
development of transformative high-risk, high-reward advances in computer and
information science, engineering, mathematics, statistics, behavioral and/or
cognitive research to address pressing questions in the biomedical and public
health communities.  Transformations hinge on scientific and engineering
innovations by interdisciplinary teams that develop novel methods to intuitively
and intelligently collect, sense, connect, analyze and interpret data from
individuals, devices and systems to enable discovery and optimize health.
Solutions to these complex biomedical or public health problems demand the
formation of interdisciplinary teams that are ready to address these issues, while
advancing fundamental science and engineering. Application due date: February
16, 2021.  For more information visit:
https://www.nsf.gov/pubs/2021/nsf21530/nsf21530.htm
SMART HEALTH & BIOMEDICAL RESEARCH IN THE ERA OF
ARTIFICIAL INTELLIGENCE & ADVANCED DATA SCIENCE
(SCH): DUE  FEB .  16 ,  2021  AT  5  PM
New understanding and/or diagnosis of a disease process
New devices, therapeutics, and vaccines for the treatment and/or prevention
of disease
New standards of care in the practice of community medicine
New approaches to community-based research demonstrating true bi-
directionality between community and academia
New methodologies to leverage institutional strengths and 
The pursuit of high-risk, high reward studies
The UMCCTS and Worcester Polytechnic Institute (WPI) are announcing the next
funding round for the Pilot Project Program (PPP). Individual project awards (up
to $50,000 for 1 year) will be made on a competitive basis to enable investigators
to accelerate the translation of innovative discoveries into:
new initiatives
For more information visit:  https ://umassmed .edu/ccts/funding/PPP/
UMCCTS PILOT PROJECT PROGRAM (PPP) 2021 - 
REQUEST FOR LETTERS OF INTENT DUE  FEBRUARY  12 ,  2021  BY  5PM
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The NCI-funded PRACCTIS program (Prevention and Control of Cancer:
Training for Change in Individuals and Systems) at UMMS is now accepting
applications for postdoctoral scholars to start January 2021 and August 2021.
We train independent researchers to address critical prevention and control
care delivery issues across the cancer continuum, including primary prevention,
screening, diagnosis, treatment and survivorship, with emphasis on promoting
change in individuals, providers and systems. Our faculty mentors are leaders
in implementation science, health equity and low resource settings, health
behavior change, health informatics, systems change and health policy, health
communications, population health sciences, and prevention and intervention
research. Applicants must plan to pursue an independent research career focused
on cancer prevention and control, have earned a doctoral degree (PhD, ScD, MD,
DO, etc.), and be a U.S. citizen or permanent resident. For more information
contact Barbara Estabrook, Barbara.estabrook@umasmed.edu
POSTDOCTORAL TRAINING IN CANCER 
PREVENTION & CONTROL:
The Translational Science Interagency Fellowship (TSIF) is a new post doctoral
fellowship opportunity developed by the National Center for Advancing
Translational Sciences (NCATS) and the U.S. Food and Drug Administration
(FDA).Fellows will be jointly mentored by NCATS and FDA scientists on a research
project of mutual interest to both organizations. Fellows in this program will
develop skills of value to future careers in academia, the pharmaceutical industry
and government.  Applicants must be US citizens or permanent residents and have
two years or less of postdoctoral training. More information about potential projects,
mentors, and the application process can be found at https://ncats.nih.gov/training-
education/training/TSIF .  Questions about the fellowship and application process
are welcome. Please contact TSIFellowship@nih.gov (link sends e-mail)
TRANSLATIONAL SCIENCE INTERAGENCY FELLOWSHIP:
JANUARY 2021 PAGE | 07
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The Human Research Protection Program (HRPP) Quality Assurance/Quality
Improvement (QA/QI) Program is a component of the UMass Center for Clinical
and Translational Science. The program is independent of the IRB and helps study
teams and investigators by conducting routine post-approval monitoring of on-
going research to evaluate adherence with institutional requirements and federal
regulations. If there are review findings, the QA/QI manager shares those findings
with investigators and study teams, and provides direct education on the findings,
including how to avoid making similar errors in the future. In order to support
improvement at an institutional level, the QA/QI manager shares aggregated data
from reviews with the HRPP leadership and the Research Community to identify
trends and target areas for education. The program also makes self-evaluation
tools available to investigators and study teams seeking to perform their own
assessments.  To learn more about HRPP QA/QI HRP-142,
visit: https://www.umassmed.edu/globalassets/ccts/ccts-media/irb/updated-sops-
2015/hrp-142-hrpp-qa-qi-program-final.pdf.
The goal of CD2H is to make data more meaningful, open and accessible. The
CD2H supports a vibrant and evolving collaborative informative ecosystem for the
CTSA program and beyond. The CD2H harnesses and expands an ecosystem for
translational scientists to discover and share their software, data and other
research resources within the CTSA program network.  The CD2H also creates a
social coding environment for translational science institutions, leveraging the
community-driven DREAM challenges as a mechanism to stimulate innovation. To
learn more,  https ://ctsa .ncats .nih .gov/cd2h/.
NATIONAL CENTER FOR DATA TO HEALTH (CD2H):
DID  YOU  KNOW?
HRPP QA/QI:
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Please cite the NIH CTSA award any time you use The UMMS Center for
Clinical and Translational Science resources, services and facilities or
received funding through the Center. “The project described is
supported by the National Center for Advancing Translational Sciences,
National Institutes of Health, through Grant UL1 TR001453, (or TL1
TR001454, or KL2 TR001455, as appropriate). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIH.”
CITE  & SUBMIT
Tufts CTSI Clinical Research Network is hosting the “Research with Sexual and
Gender Minority Populations” training module which will be led by Tania D. Strout,
PhD, RN, MS from Maine Medical Center.  Please register at:
https://ilearn.tuftsctsi.org/product?catalog=ST109_2019_Online
EDUCATION
RESEARCH WITH SEXUAL & GENDER MINORITY POPULATIONS
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To be included in the CCTS Monthly Newsletter , please send announcements , including
a link , to ccts@umassmed .edu . The newsletter is published the first week of each
month .
NEWSLETTER  SUBMISSIONS
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 55  LAKE  AVENUE  N ,  WORCESTER  MA  01655
SHARE YOUR SUCCESS STORY!
Have you had your research published that cites
the UMass Center for Clinical and Translational
Science?  Has your patent been filed on technology
developed using Center funding or resources? Did
your pilot project receive external grant funding?
Share it with us at ccts@umassmed.edu. Sharing
your success demonstrates the importance and
effect of the Center for Clinical and Translational
Science at UMass.
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